We aimed to gain insight into the real-world prevalence of potentially significant drug-drug interactions (DDIs) involving oral antineoplastic agents using nationwide data in Korea.
The data from the 2016 and 2017 Health Insurance Review and Assessment Service-National Patients Sample (HIRA-NPS) of South Korea were used. The drugs prescribed concomitantly with oral anticancer drugs were screened for the potential DDIs by using two international DDI databases: LexicompTM and Micromedex®. Potentially significant DDIs were defined as DDIs with a severity rating of “major” or higher from at least one reference. The DDIs were classified into category 1 if the severity ratings were major or higher using both references.
Overall 5657 cases of DDIs in 2925 patients (26.4%) and 1640 cases of category 1 DDIs in 997 patients (9.0%) were identified among 11,076 patients receiving oral anticancer drugs. The prevalence was highest among the targeted agents (63.2%) followed by traditional (21.2%) and endocrine agents (19.3%). The common potential clinical consequences were increased risk of corrected QT interval prolongation (36.7%), reduced efficacy of antineoplastic agents (30.4%), and increased toxicities of antineoplastic agents (8.0%). Polypharmacy and the duration of oral cancer treatment increased the likelihood of potential DDIs in addition to individual antineoplastic agents.
This study showed that potentially significant DDIs with oral antineoplastic agents were prevalent in real-world practice. Recognizing the high prevalence of DDIs among patients taking oral antineoplastic agents is a necessary step toward improving the clinical outcome.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Scripture CD, Figg WD (2006) Drug interactions in cancer therapy. Nat Rev Cancer 6(7):546–558. https://doi.org/10.1038/nrc1887
Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H (2017) A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol 11(Suppl 5):87. https://doi.org/10.1186/s12918-017-0464-7
Sharma M, Vadhariya A, Chikermane S, Gopinathan S, Chavez-MacGregor M, Giordano SH, Johnson ML, Holmes HM (2019) Clinical outcomes associated with drug-drug interactions of oral chemotherapeutic agents: a comprehensive evidence-based literature review. Drugs Aging 36(4):341–354. https://doi.org/10.1007/s40266-019-00640-5
Herbrink M, Nuijen B, Schellens JH, Beijnen JH (2015) Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev 41(5):412–422. https://doi.org/10.1016/j.ctrv.2015.03.005
Rogala BG, Charpentier MM, Nguyen MK, Landolf KM, Hamad L, Gaertner KM (2019) Oral anticancer therapy: Management of drug interactions. J Oncol Pract 15(2):81–90. https://doi.org/10.1200/JOP.18.00483
Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99(8):592–600. https://doi.org/10.1093/jnci/djk130
Vecchia S, Orlandi E, Confalonieri C, Damonti E, Riva A, Sartori A, Cavanna L (2018) Prevalence study on potential drug-drug interaction in cancer patients in Piacenza hospital’s Onco-Haematology department. J Oncol Pharm Pract 24(7):490–493. https://doi.org/10.1177/1078155217717324
Ko Y, Tan S-LD, Chan A, Wong Y-P, Yong W-P, Ng RC-H, Lim S-W, Salim A (2012) Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Clin Ther 34(8):1696–1704. https://doi.org/10.1016/j.clinthera.2012.06.025
Andersson ML, Bottiger Y, Kockum H, Eiermann B (2018) High prevalence of drug-drug interactions in primary health care is caused by prescriptions from other healthcare units. Basic Clin Pharmacol Toxicol 122(5):512–516. https://doi.org/10.1111/bcpt.12939
Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, Mehra N, van Erp NP (2018) Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. Br J Clin Pharmacol 84(1):122–129. https://doi.org/10.1111/bcp.13425
Armahizer MJ, Kane-Gill SL, Smithburger PL, Anthes AM, Seybert AL (2013) Comparing drug-drug interaction severity ratings between bedside clinicians and proprietary databases. ISRN Crit Care 2013:1–6. https://doi.org/10.5402/2013/347346
Solomon JM, Ajewole VB, Schneider AM, Sharma M, Bernicker EH (2018) Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center. J Oncol Pharm Pract. https://doi.org/10.1177/1078155218798150
van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, Jansman FG (2013) Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108(5):1071–1078. https://doi.org/10.1038/bjc.2013.48
Gustafson E, Kettle J (2015) Analyzing trends in oral anticancer agents in an academic medical facility. J Hematol Oncol Pharm 5:34–37
Porta-Sanchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, Thavendiranathan P (2017) Incidence, diagnosis, and management of qt prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc 6(12). https://doi.org/10.1161/jaha.117.007724
Keller KL, Franquiz MJ, Duffy AP, Trovato JA (2018) Drug-drug interactions in patients receiving tyrosine kinase inhibitors. J Oncol Pharm Pract 24(2):110–115. https://doi.org/10.1177/1078155216682311
van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG (2014) Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 15(8):e315–e326. https://doi.org/10.1016/s1470-2045(13)70579-5
Colzani E, Clements M, Johansson AL, Liljegren A, He W, Brand J, Adolfsson J, Fornander T, Hall P, Czene K (2016) Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. Br J Cancer 115(11):1400–1407. https://doi.org/10.1038/bjc.2016.314
Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y (2009) Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67(1):44–49. https://doi.org/10.1111/j.1365-2125.2008.03303.x
Chan AJ, Rajakumar I (2014) High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity. J Oncol Pharm Pract 20(2):93–99. https://doi.org/10.1177/1078155213482602
Shetty V, Chowta MN, Chowta KN, Shenoy A, Kamath A, Kamath P (2018) Evaluation of potential drug-drug interactions with medications prescribed to geriatric patients in a tertiary care hospital. J Aging Res 2018:5728957. https://doi.org/10.1155/2018/5728957
Wang W, Xiao B, Liu Z, Wang D, Zhu M (2019) The prevalence of the potential drug-drug interactions involving anticancer drugs in china: a retrospective study. Iran J Public Health 48(3):435–443
This work was supported by Research Resettlement Fund for the new faculty of Seoul National University.
The protocol of this study was approved by the Seoul National University institutional review board (SNU 18-09-055).
Conflict of Interest
The authors declare that they have no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The first two authors contribute equally and should be considered joint first author.
Electronic supplementary material
About this article
Cite this article
Kim, S.H., Suh, Y., Ah, YM. et al. Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study. Support Care Cancer 28, 3617–3626 (2020). https://doi.org/10.1007/s00520-019-05204-2
- Oral antineoplastic agents
- Drug interaction
- QTc prolongation